The company is testing the assay's potential as a tool to manage the treatment of patients with primary breast cancer.
The US National Institute of Mental Health has funded fewer clinical trials since it began to emphasize studies of the biological basis of disease, Nature News reports.
A new analysis has uncovered clinical trial papers that have reported suspicious data, the Guardian reports.
There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.
Data presented at ASCO showing 76 percent of cancer patients responded to larotrectinib could lead to the availability of the first tissue-agnostic targeted drug.
Clinical embryonic stem cell trials are set to begin in China, according to Nature News.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
The company presented data demonstrating that ADHD patients with mutations in nine genes had a clinically meaningful and statistically significant response to AEVI-001.
Grail plans to enroll up to 120,000 women who have been screened via mammogram, to train and validate its NGS-based early detection cancer test.
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.